(Q85041884)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847743%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Developing drug prototypes: pharmacology replaces safety and tolerability? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847743%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

adverse drug reaction

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20847743

14 July 2024

author name string

Adam F. Cohen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20847743

14 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20847743

14 July 2024

publication date

17 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847743%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

14 February 2020

http://www.nature.com/articles/nrd3227.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/NRD3227

http://www.nature.com/articles/nrd3227

14 July 2024

1 reference

https://api.crossref.org/works/10.1038/NRD3227

Nature Reviews Drug Discovery

14 July 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847743%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847743%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847743%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

856-865

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847743%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd3227

14 February 2020

exact match

0 references

cites work

Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.

1 reference

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

31 March 2020

1 reference

A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for athe

31 March 2020

1 reference

Commercializing clinical trials--risks and benefits of the CRO boom

31 March 2020

1 reference

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

31 March 2020

1 reference

Drug discovery in jeopardy

31 March 2020

1 reference

Lessons from 60 years of pharmaceutical innovation

31 March 2020

1 reference

Learning versus confirming in clinical drug development

31 March 2020

1 reference

Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers

31 March 2020

1 reference

Establishing risk of human experimentation with drugs: lessons from TGN1412.

31 March 2020

1 reference

Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies

31 March 2020

1 reference

Should we tolerate tolerability as an objective in early drug development?

31 March 2020

1 reference

The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man

31 March 2020

1 reference

Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919).

31 March 2020

1 reference

First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist

31 March 2020

1 reference

Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries.

31 March 2020

1 reference

The strange case of TGN1412

31 March 2020

1 reference

Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in "human immune system" Rag2(-/-)gammac(-/-) mice

31 March 2020

1 reference

Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients.

31 March 2020

1 reference

Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients.

31 March 2020

1 reference

Biomarkers for the effects of benzodiazepines in healthy volunteers

31 March 2020

1 reference

Promotion of sleep by targeting the orexin system in rats, dogs and humans

31 March 2020

1 reference

Joining the DoTS: new approach to classifying adverse drug reactions

31 March 2020

1 reference

31 March 2020

1 reference

Clinical pharmacology in the molecular era.

31 March 2020

1 reference

Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects

31 March 2020

1 reference

Rebuilding the R&D engine in big pharma

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20847743

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20847743

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

TGN1412: time to change the paradigm for the testing of new pharmaceuticals

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20847743